Market cap
$1,889 Mln
Revenue (TTM)
$103 Mln
P/E Ratio
39
P/B Ratio
4.5
Div. Yield
0 %
| BioLife Solutions (BLFS) | Glaukos Corp (GKOS) | Penumbra (PEN) | Repligen (RGEN) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
1,889 | 14,620 | 12,647 | 10,726 | 10,488 |
Revenue ($ Mln) |
103 | 690 | 1,560 | 806 | 2,593 |
Net Profit ($ Mln) |
50.45 | -169.80 | 157.02 | -11.80 | 1,022.90 |
Net Margin (%) |
49.06 | -24.60 | 10.06 | -1.47 | 39.45 |
RoE (%) |
12.74 | -24.46 | 10.27 | -0.56 | 14.15 |
Price to Earnings |
39.00 | -- | 80.82 | -- | 10.36 |
Price-To-Book |
4.50 | 20.40 | 7.98 | 5.09 | 1.38 |
Income Statement ($ Mln)
| BioLife Solutions (BLFS) | Glaukos Corp (GKOS) | Penumbra (PEN) | Repligen (RGEN) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Operating Revenue
|
102.82 | 690.33 | 1,560.33 | 805.61 | 2,592.70 |
|
Cost of Revenue
|
36.52 | 130.29 | 499.55 | 394.34 | 1,263.70 |
|
Gross Profit
|
62.12 | 393.22 | 942.44 | 347.62 | 1,343.60 |
|
Operating Expenses
|
58.84 | 623.34 | 871.54 | 392.34 | 1,209.10 |
|
Operating Profit (EBIT)
|
7.45 | -63.30 | 189.25 | 18.93 | 118.90 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
8.07 | -174.52 | 207.82 | 8.23 | 1,320.20 |
|
Provision for Tax
|
-42.38 | -4.72 | 50.81 | 20.03 | 297.30 |
|
Profit after Tax (Net Income)
|
50.45 | -169.80 | 157.02 | -11.80 | 1,022.90 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Consolidated Profit
|
0.00 | 0.00 | 47.34 | 0.00 | 0.00 |
Liabilities ($ Mln)
| BioLife Solutions (BLFS) | Glaukos Corp (GKOS) | Penumbra (PEN) | Repligen (RGEN) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
420.00 | 717.27 | 1,583.51 | 2,091.74 | 7,603.00 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Non-Current Liabilities
|
13.54 | 135.53 | 207.78 | 708.99 | 2,211.00 |
|
Current Liabilities
|
13.95 | 126.73 | 233.81 | 125.69 | 969.10 |
|
Total Liabilities
|
405.88 | 893.49 | 1,826.52 | 2,949.70 | 10,576.50 |
Assets ($ Mln)
| BioLife Solutions (BLFS) | Glaukos Corp (GKOS) | Penumbra (PEN) | Repligen (RGEN) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
312.30 | 399.88 | 648.47 | 1,684.42 | 7,704.50 |
|
Current Assets
|
135.20 | 579.65 | 1,376.63 | 1,241.98 | 3,078.60 |
|
Total Assets
|
405.88 | 893.49 | 1,826.52 | 2,949.70 | 10,576.50 |
|
Total Debt*
|
15.74 | 101.98 | 209.39 | 692.24 | 1,363.40 |
|
Net Current Assets
|
121.25 | 452.92 | 1,142.82 | 1,116.30 | 2,109.50 |
Cashflow ($ Mln)
| BioLife Solutions (BLFS) | Glaukos Corp (GKOS) | Penumbra (PEN) | Repligen (RGEN) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
20.12 | -46.34 | 238.66 | 117.42 | 532.20 |
|
Cash Flow from Investing Activities
|
-71.54 | -77.61 | -404.59 | -298.47 | -189.70 |
|
Cash from Financing Activities
|
-10.92 | 11.89 | 26.53 | -15.21 | -283.20 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| BioLife Solutions (BLFS) | Glaukos Corp (GKOS) | Penumbra (PEN) | Repligen (RGEN) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-3.16 | -22.53 | 11.76 | 1.79 | 8.98 |
|
ROE (%)
|
12.74 | -24.46 | 10.27 | -0.56 | 14.15 |
|
ROA (%)
|
11.50 | -15.48 | 7.53 | -0.39 | 9.31 |
|
EBIT Margin (%)
|
6.03 | -24.51 | 13.40 | 4.20 | 52.80 |
|
Net Margin (%)
|
49.06 | -24.60 | 10.06 | -1.47 | 39.45 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| BioLife Solutions (BLFS) | Glaukos Corp (GKOS) | Penumbra (PEN) | Repligen (RGEN) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
34.39 | 46.94 | 16.98 | 13.80 | 1.38 |
|
EBIT Growth (%)
|
146.48 | -106.70 | 11.72 | 29.47 | 272.53 |
|
Net Profit Growth (%)
|
1,012.22 | -93.80 | -4.27 | -779.17 | 251.34 |
|
EPS Growth (%)
|
965.62 | -90.00 | -4.95 | -910.66 | 256.24 |
|
Book Value Growth (%)
|
17.31 | -12.58 | 15.61 | 0.35 | 12.77 |
Valuation Ratios
| BioLife Solutions (BLFS) | Glaukos Corp (GKOS) | Penumbra (PEN) | Repligen (RGEN) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-96.97 | -34.59 | 68.93 | 189.42 | -- |
|
Price / Book Value
|
3.16 | 9.90 | 8.58 | 4.40 | -- |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
306.49 | -43.50 | 53.25 | 50.32 | -- |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| BioLife Solutions (BLFS) | Glaukos Corp (GKOS) | Penumbra (PEN) | Repligen (RGEN) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.00 | 0.00 | 0.27 | 0.11 |
|
Short term debt to equity ratio
|
0.01 | 0.00 | 0.01 | 0.01 | 0.06 |
|
Current Ratio
|
9.69 | 4.57 | 5.89 | 9.88 | 3.18 |
|
Quick Ratio
|
7.14 | 4.09 | 3.92 | 8.43 | 2.37 |
|
Interest Coverage
|
13.22 | -35.23 | 165.16 | 1.24 | 28.05 |
Operating Efficiency Ratios
| BioLife Solutions (BLFS) | Glaukos Corp (GKOS) | Penumbra (PEN) | Repligen (RGEN) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
10.36 | 21.73 | 12.51 | 18.77 | 16.30 |
|
Asset Turnover
|
0.23 | 0.63 | 0.75 | 0.26 | 0.24 |
|
Receivable days
|
32.50 | 60.95 | 46.54 | 72.41 | 65.39 |
|
Inventory Days
|
316.92 | 193.84 | 331.92 | 146.53 | 221.09 |
|
Payable days
|
27.10 | 60.19 | 26.16 | 29.05 | 37.02 |
|
Cash Conversion Cycle
|
322.32 | 194.60 | 352.30 | 189.88 | 249.46 |